JAK2 and hematologic disorder: Ruxolitinib was already Food and Drug Administration approved in 2011 based on the positive results of the COMFORT‐I clinical trial.40 Somatic mutations rendering JAK2 constitutively active like the V617F mutation are often found in hematologic malignancies.